biote (BTMD) Competitors $4.24 -0.13 (-2.97%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$4.26 +0.01 (+0.35%) As of 03/3/2025 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends BTMD vs. GYRE, ZYME, COLL, RCUS, RCKT, PAHC, EOLS, ABCL, AVBP, and OCSShould you be buying biote stock or one of its competitors? The main competitors of biote include Gyre Therapeutics (GYRE), Zymeworks (ZYME), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), Phibro Animal Health (PAHC), Evolus (EOLS), AbCellera Biologics (ABCL), ArriVent BioPharma (AVBP), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. biote vs. Gyre Therapeutics Zymeworks Collegium Pharmaceutical Arcus Biosciences Rocket Pharmaceuticals Phibro Animal Health Evolus AbCellera Biologics ArriVent BioPharma Oculis biote (NASDAQ:BTMD) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Does the media favor BTMD or GYRE? In the previous week, Gyre Therapeutics had 1 more articles in the media than biote. MarketBeat recorded 3 mentions for Gyre Therapeutics and 2 mentions for biote. biote's average media sentiment score of 0.93 beat Gyre Therapeutics' score of 0.29 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, BTMD or GYRE? biote has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Is BTMD or GYRE more profitable? biote has a net margin of 5.20% compared to Gyre Therapeutics' net margin of -84.57%. biote's return on equity of -32.41% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets biote5.20% -32.41% 22.26% Gyre Therapeutics -84.57%-118.43%-71.97% Do analysts recommend BTMD or GYRE? biote presently has a consensus target price of $10.50, suggesting a potential upside of 147.64%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of BTMD or GYRE? 21.7% of biote shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 13.9% of biote shares are owned by company insiders. Comparatively, 19.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings and valuation, BTMD or GYRE? biote has higher revenue and earnings than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$193.06M1.19$3.32M$0.2616.31Gyre Therapeutics$105.03M10.18-$92.93MN/AN/A Does the MarketBeat Community prefer BTMD or GYRE? biote received 14 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformbioteOutperform Votes14100.00% Underperform VotesNo VotesGyre TherapeuticsN/AN/A Summarybiote beats Gyre Therapeutics on 10 of the 15 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.39M$1.14B$5.81B$8.40BDividend YieldN/AN/A4.75%3.98%P/E Ratio16.3135.1024.9519.25Price / Sales1.195.21375.55110.22Price / Cash9.6010.4038.0534.58Price / Book-7.311.837.334.28Net Income$3.32M-$53.22M$3.18B$247.04M7 Day Performance-3.64%-5.70%-2.87%-3.25%1 Month Performance-16.37%-10.64%-6.77%-6.55%1 Year Performance-23.05%-19.36%12.32%4.01% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.9077 of 5 stars$4.24-3.0%$10.50+147.6%-27.4%$230.39M$193.06M16.31194Upcoming EarningsGYREGyre Therapeutics0.0982 of 5 stars$10.55-8.6%N/A-44.5%$986.65M$105.03M0.0040ZYMEZymeworks2.1806 of 5 stars$13.95-3.1%$19.17+37.4%+1.8%$960.85M$62.20M-9.30460COLLCollegium Pharmaceutical4.215 of 5 stars$29.19+0.2%$43.60+49.4%-23.4%$941.38M$599.25M12.58210Earnings ReportRCUSArcus Biosciences2.6702 of 5 stars$10.16-8.2%$29.50+190.3%-44.9%$930.02M$117M-3.23500Earnings ReportRCKTRocket Pharmaceuticals4.6988 of 5 stars$10.05-4.0%$47.27+370.4%-71.2%$916.13MN/A-3.65240Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePAHCPhibro Animal Health3.5348 of 5 stars$22.12-1.7%$21.00-5.1%+83.1%$895.93M$1.11B46.081,940Gap UpEOLSEvolus3.9756 of 5 stars$14.11+0.9%$23.67+67.7%-3.8%$893.46M$248.33M-15.51170ABCLAbCellera Biologics2.3859 of 5 stars$2.99-1.3%$8.00+167.6%-53.3%$883.16M$38.03M-4.90500Analyst ForecastAVBPArriVent BioPharma1.4736 of 5 stars$25.26-6.7%$38.00+50.4%+5.2%$851.26MN/A0.0040Earnings ReportNews CoveragePositive NewsOCSOculis2.2845 of 5 stars$20.88-2.5%$28.80+37.9%+62.8%$845.72M$980,000.00-10.822Short Interest ↑ Related Companies and Tools Related Companies Gyre Therapeutics Alternatives Zymeworks Alternatives Collegium Pharmaceutical Alternatives Arcus Biosciences Alternatives Rocket Pharmaceuticals Alternatives Phibro Animal Health Alternatives Evolus Alternatives AbCellera Biologics Alternatives ArriVent BioPharma Alternatives Oculis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTMD) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
